請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56372
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 田蕙芬(Hwei-Fang Tien),周文堅(Wen-Chien Chou) | |
dc.contributor.author | Yu-Hung Wang | en |
dc.contributor.author | 王昱弘 | zh_TW |
dc.date.accessioned | 2021-06-16T05:25:34Z | - |
dc.date.available | 2020-08-26 | |
dc.date.copyright | 2020-08-26 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-07-31 | |
dc.identifier.citation | . (2019). In E. Carreras, C. Dufour, M. Mohty, N. Kröger (Eds.), The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. Cham (CH): Springer Copyright 2019, The Editor(s) (if applicable) and The Author(s). Akpek, G., Pasquini, M. C., Logan, B., Agovi, M. A., Lazarus, H. M., Marks, D. I., . . . Marrow Transplant, R. (2013). Effects of spleen status on early outcomes after hematopoietic cell transplantation. Bone Marrow Transplantation, 48(6), 825-831. doi:10.1038/bmt.2012.249 Aoudjhane, M., Labopin, M., Gorin, N. C., Shimoni, A., Ruutu, T., Kolb, H. J., . . . Rocha, V. (2005). Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia, 19(12), 2304-2312. doi:10.1038/sj.leu.2403967 Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., . . . Vardiman, J. W. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127(20), 2391-2405. doi:10.1182/blood-2016-03-643544 Bacigalupo, A., Ballen, K., Rizzo, D., Giralt, S., Lazarus, H., Ho, V., . . . Horowitz, M. (2009). Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant, 15(12), 1628-1633. doi:10.1016/j.bbmt.2009.07.004 Ballen, K. K., Shrestha, S., Sobocinski, K. A., Zhang, M. J., Bashey, A., Bolwell, B. J., . . . Arora, M. (2010). Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant, 16(3), 358-367. doi:10.1016/j.bbmt.2009.10.025 Barbui, T., Thiele, J., Gisslinger, H., Kvasnicka, H. M., Vannucchi, A. M., Guglielmelli, P., . . . Tefferi, A. (2018). The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J, 8(2), 15. doi:10.1038/s41408-018-0054-y Barosi, G., Mesa, R. A., Thiele, J., Cervantes, F., Campbell, P. J., Verstovsek, S., . . . Tefferi, A. (2008). Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia, 22(2), 437-438. doi:10.1038/sj.leu.2404914 Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J. T., Morra, E., . . . Tefferi, A. (2009). New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 113(13), 2895-2901. doi:10.1182/blood-2008-07-170449 Cervantes, F., Mesa, R., Barosi, G. (2007). New and old treatment modalities in primary myelofibrosis. Cancer J, 13(6), 377-383. doi:10.1097/PPO.0b013e31815a7c0a Coltro, G., Mannelli, F., Guglielmelli, P., Pacilli, A., Bosi, A., Vannucchi, A. M. (2017). A life-threatening ruxolitinib discontinuation syndrome. Am J Hematol, 92(8), 833-838. doi:10.1002/ajh.24775 Deeg, H. J., Gooley, T. A., Flowers, M. E., Sale, G. E., Slattery, J. T., Anasetti, C., . . . Appelbaum, F. R. (2003). Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood, 102(12), 3912-3918. doi:10.1182/blood-2003-06-1856 Deeg, H. J., Storer, B., Slattery, J. T., Anasetti, C., Doney, K. C., Hansen, J. A., . . . Appelbaum, F. R. (2002). Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood, 100(4), 1201-1207. doi:10.1182/blood-2002-02-0527 Elliott, M. A., Chen, M. G., Silverstein, M. N., Tefferi, A. (1998). Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol, 103(2), 505-511. doi:10.1046/j.1365-2141.1998.00998.x Elliott, M. A., Mesa, R. A., Li, C. Y., Hook, C. C., Ansell, S. M., Levitt, R. M., . . . Tefferi, A. (2002). Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol, 117(2), 288-296. doi:10.1046/j.1365-2141.2002.03443.x Guardiola, P., Anderson, J. E., Bandini, G., Cervantes, F., Runde, V., Arcese, W., . . . Gluckman, E. (1999). Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood, 93(9), 2831-2838. Guglielmelli, P., Lasho, T. L., Rotunno, G., Mudireddy, M., Mannarelli, C., Nicolosi, M., . . . Tefferi, A. (2018). MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. J Clin Oncol, 36(4), 310-318. doi:10.1200/jco.2017.76.4886 Guglielmelli, P., Lasho, T. L., Rotunno, G., Score, J., Mannarelli, C., Pancrazzi, A., . . . Tefferi, A. (2014). The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia, 28(9), 1804-1810. doi:10.1038/leu.2014.76 Guglielmelli, P., Pacilli, A., Rotunno, G., Rumi, E., Rosti, V., Delaini, F., . . . Vannucchi, A. M. (2017). Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood, 129(24), 3227-3236. doi:10.1182/blood-2017-01-761999 Guglielmelli, P., Rotunno, G., Pacilli, A., Rumi, E., Rosti, V., Delaini, F., . . . Vannucchi, A. M. (2016). Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. Am J Hematol, 91(9), 918-922. doi:10.1002/ajh.24442 Gupta, V., Kröger, N., Aschan, J., Xu, W., Leber, B., Dalley, C., . . . Brune, M. (2009). A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis. Bone Marrow Transplant, 44(5), 317-320. doi:10.1038/bmt.2009.10 Harrison, C., Kiladjian, J. J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., . . . Barosi, G. (2012). JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med, 366(9), 787-798. doi:10.1056/NEJMoa1110556 Hassan, M. (1999). The role of busulfan in bone marrow transplantation. Med Oncol, 16(3), 166-176. doi:10.1007/bf02906128 Huang, J., Tefferi, A. (2009). Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol, 83(2), 154-155. doi:10.1111/j.1600-0609.2009.01266.x Kerbauy, D. M., Gooley, T. A., Sale, G. E., Flowers, M. E., Doney, K. C., Georges, G. E., . . . Deeg, H. J. (2007). Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant, 13(3), 355-365. doi:10.1016/j.bbmt.2006.11.004 Kharfan-Dabaja, M. A., Labopin, M., Bazarbachi, A., Hamladji, R. M., Blaise, D., Socié, G., . . . Mohty, M. (2014). Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT. Bone Marrow Transplant, 49(9), 1170-1175. doi:10.1038/bmt.2014.133 Khoury, H. J., Langston, A. A., Kota, V. K., Wilkinson, J. A., Pusic, I., Jillella, A., . . . DiPersio, J. F. (2018). Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease. Bone Marrow Transplant, 53(7), 826-831. doi:10.1038/s41409-017-0081-5 Kröger, N. M., Deeg, J. H., Olavarria, E., Niederwieser, D., Bacigalupo, A., Barbui, T., . . . Barosi, G. (2015). Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia, 29(11), 2126-2133. doi:10.1038/leu.2015.233 Kröger, N., Holler, E., Kobbe, G., Bornhäuser, M., Schwerdtfeger, R., Baurmann, H., . . . de Witte, T. M. (2009). Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood, 114(26), 5264-5270. doi:10.1182/blood-2009-07-234880 Kvasnicka, H. M., Thiele, J. (2010). Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol, 85(1), 62-69. doi:10.1002/ajh.21543 Laszlo, J., Huang, A. T. (1977). Diagnosis and management of myeloproliferative disorders. Curr Probl Cancer, 2(1), 1-42. doi:10.1016/s0147-0272(77)80003-2 Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P., . . . Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med, 6(7), e1000100. doi:10.1371/journal.pmed.1000100 Lissandre, S., Bay, J. O., Cahn, J. Y., Porcher, R., Cacheux, V., Cabrespine, A., . . . Robin, M. (2011). Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis. Bone Marrow Transplant, 46(4), 557-561. doi:10.1038/bmt.2010.276 Martínez-Trillos, A., Gaya, A., Maffioli, M., Arellano-Rodrigo, E., Calvo, X., Díaz-Beyá, M., Cervantes, F. (2010). Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol, 89(12), 1233-1237. doi:10.1007/s00277-010-1019-9 McLornan, D., Szydlo, R., Koster, L., Chalandon, Y., Robin, M., Wolschke, C., . . . Yakoub-Agha, I. (2019). Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant, 25(11), 2167-2171. doi:10.1016/j.bbmt.2019.06.034 Merup, M., Lazarevic, V., Nahi, H., Andreasson, B., Malm, C., Nilsson, L., . . . Birgegård, G. (2006). Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br J Haematol, 135(3), 367-373. doi:10.1111/j.1365-2141.2006.06302.x Mesa, R. A., Steensma, D. P., Pardanani, A., Li, C. Y., Elliott, M., Kaufmann, S. H., . . . Tefferi, A. (2003). A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood, 101(7), 2534-2541. doi:10.1182/blood-2002-09-2928 Mohty, M., Labopin, M., Volin, L., Gratwohl, A., Socié, G., Esteve, J., . . . Rocha, V. (2010). Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood, 116(22), 4439-4443. doi:10.1182/blood-2010-02-266551 Mudireddy, M., Gangat, N., Lasho, T. L., Finke, C., Hanson, C. A., Ketterling, R. P., . . . Tefferi, A. (2018). Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis. Am J Hematol, 93(9), E235-e238. doi:10.1002/ajh.25203 Mudireddy, M., Shah, S., Lasho, T., Barraco, D., Hanson, C. A., Ketterling, R. P., . . . Tefferi, A. (2018). Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons. Br J Haematol, 182(4), 594-597. doi:10.1111/bjh.14838 Nagler, A., Labopin, M., Berger, R., Bunjes, D., Campos, A., Socié, G., . . . Rocha, V. (2014). Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome. Bone Marrow Transplant, 49(5), 628-633. doi:10.1038/bmt.2014.7 Nagler, A., Rocha, V., Labopin, M., Unal, A., Ben Othman, T., Campos, A., . . . Mohty, M. (2013). Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation. J Clin Oncol, 31(28), 3549-3556. doi:10.1200/jco.2013.48.8114 Nicolosi, M., Mudireddy, M., Lasho, T. L., Hanson, C. A., Ketterling, R. P., Gangat, N., . . . Tefferi, A. (2018). Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. Leukemia, 32(5), 1254-1258. doi:10.1038/s41375-018-0028-x Passamonti, F., Cervantes, F., Vannucchi, A. M., Morra, E., Rumi, E., Pereira, A., . . . Tefferi, A. (2010). A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood, 115(9), 1703-1708. doi:10.1182/blood-2009-09-245837 Patriarca, F., Bacigalupo, A., Sperotto, A., Isola, M., Soldano, F., Bruno, B., . . . Bosi, A. (2008). Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica, 93(10), 1514-1522. doi:10.3324/haematol.12828 Pieri, L., Paoli, C., Arena, U., Marra, F., Mori, F., Zucchini, M., . . . Vannucchi, A. M. (2017). Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. Am J Hematol, 92(2), 187-195. doi:10.1002/ajh.24614 Quintás-Cardama, A., Kantarjian, H. M., Manshouri, T., Thomas, D., Cortes, J., Ravandi, F., . . . Verstovsek, S. (2009). Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol, 27(28), 4760-4766. doi:10.1200/jco.2009.22.6548 Rondelli, D., Goldberg, J. D., Isola, L., Price, L. S., Shore, T. B., Boyer, M., . . . Hoffman, R. (2014). MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood, 124(7), 1183-1191. doi:10.1182/blood-2014-04-572545 Rumi, E., Pietra, D., Pascutto, C., Guglielmelli, P., Martínez-Trillos, A., Casetti, I., . . . Investigators, o. b. o. t. A. I. p. l. R. s. C. G. I. M. M. (2014). Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood, 124(7), 1062-1069. doi:10.1182/blood-2014-05-578435 Samuelson Bannow, B. T., Salit, R. B., Storer, B. E., Stevens, E. A., Wu, D., Yeung, C., . . . Scott, B. L. (2018). Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes. Biol Blood Marrow Transplant, 24(2), 386-392. doi:10.1016/j.bbmt.2017.09.016 Samuelson, S., Sandmaier, B. M., Heslop, H. E., Popat, U., Carrum, G., Champlin, R. E., . . . Deeg, H. J. (2011). Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. Br J Haematol, 153(1), 76-82. doi:10.1111/j.1365-2141.2011.08582.x Schmohl, J. U., Groh, C., Faul, C., Vogel, W., Möhle, R., Wirths, S., . . . Bethge, W. A. (2016). Allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A single center experience. Ann Hematol, 95(6), 973-983. doi:10.1007/s00277-016-2644-8 Shanavas, M., Popat, U., Michaelis, L. C., Fauble, V., McLornan, D., Klisovic, R., . . . Gupta, V. (2016). Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biol Blood Marrow Transplant, 22(3), 432-440. doi:10.1016/j.bbmt.2015.10.005 Shimomura, Y., Hara, M., Katoh, D., Hashimoto, H., Ishikawa, T. (2018). Enlarged spleen is associated with low neutrophil and platelet engraftment rates and poor survival after allogeneic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome. Annals of Hematology, 97(6), 1049-1056. doi:10.1007/s00277-018-3278-9 Shimoni, A., Hardan, I., Shem-Tov, N., Rand, A., Herscovici, C., Yerushalmi, R., Nagler, A. (2007). Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan. Leukemia, 21(10), 2109-2116. doi:10.1038/sj.leu.2404886 Shimoni, A., Labopin, M., Savani, B., Volin, L., Ehninger, G., Kuball, J., . . . Nagler, A. (2016). Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. J Hematol Oncol, 9(1), 118. doi:10.1186/s13045-016-0347-1 Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., . . . Or, R. (1998). Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood, 91(3), 756-763. Slostad, J., Hoversten, P., Haddox, C. L., Cisak, K., Paludo, J., Tefferi, A. (2018). Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A single patient experience. Am J Hematol, 93(2), E47-e49. doi:10.1002/ajh.24971 Stang, A. (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 25(9), 603-605. doi:10.1007/s10654-010-9491-z Stewart, W. A., Pearce, R., Kirkland, K. E., Bloor, A., Thomson, K., Apperley, J., . . . Kottaridis, P. D. (2010). The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. Bone Marrow Transplant, 45(11), 1587-1593. doi:10.1038/bmt.2010.14 Tamari, R., Rapaport, F., Zhang, N., McNamara, C., Kuykendall, A., Sallman, D. A., . . . Rampal, R. K. (2019). Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis. Biol Blood Marrow Transplant, 25(6), 1142-1151. doi:10.1016/j.bbmt.2019.01.002 Tefferi, A. (2000). Myelofibrosis with myeloid metaplasia. N Engl J Med, 342(17), 1255-1265. doi:10.1056/nejm200004273421706 Tefferi, A. (2005). Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol, 23(33), 8520-8530. doi:10.1200/jco.2004.00.9316 Tefferi, A. (2012). JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood, 119(12), 2721-2730. doi:10.1182/blood-2011-11-395228 Tefferi, A., Cortes, J., Verstovsek, S., Mesa, R. A., Thomas, D., Lasho, T. L., . . . Kantarjian, H. M. (2006). Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood, 108(4), 1158-1164. doi:10.1182/blood-2006-02-004572 Tefferi, A., Elliot, M. A., Yoon, S. Y., Li, C. Y., Mesa, R. A., Call, T. G., Dispenzieri, A. (2001). Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood, 97(6), 1896. doi:10.1182/blood.v97.6.1896 Tefferi, A., Finke, C. M., Lasho, T. L., Hanson, C. A., Ketterling, R. P., Gangat, N., Pardanani, A. (2018). U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. Leukemia, 32(10), 2274-2278. doi:10.1038/s41375-018-0078-0 Tefferi, A., Guglielmelli, P., Lasho, T. L., Gangat, N., Ketterling, R. P., Pardanani, A., Vannucchi, A. M. (2018). MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. J Clin Oncol, 36(17), 1769-1770. doi:10.1200/jco.2018.78.9867 Tefferi, A., Guglielmelli, P., Lasho, T. L., Rotunno, G., Finke, C., Mannarelli, C., . . . Vannucchi, A. M. (2014). CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia, 28(7), 1494-1500. doi:10.1038/leu.2014.57 Tefferi, A., Guglielmelli, P., Nicolosi, M., Mannelli, F., Mudireddy, M., Bartalucci, N., . . . Vannucchi, A. M. (2018). GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia, 32(7), 1631-1642. doi:10.1038/s41375-018-0107-z Tefferi, A., Lasho, T. L., Finke, C., Gangat, N., Hanson, C. A., Ketterling, R. P., Pardanani, A. (2018). Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis. Leukemia, 32(3), 837-839. doi:10.1038/leu.2017.318 Tefferi, A., Lasho, T. L., Finke, C. M., Elala, Y., Hanson, C. A., Ketterling, R. P., . . . Pardanani, A. (2016). Targeted deep sequencing in primary myelofibrosis. Blood Adv, 1(2), 105-111. doi:10.1182/bloodadvances.2016000208 Tefferi, A., Mesa, R. A., Nagorney, D. M., Schroeder, G., Silverstein, M. N. (2000). Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood, 95(7), 2226-2233. Tefferi, A., Mudireddy, M., Mannelli, F., Begna, K. H., Patnaik, M. M., Hanson, C. A., . . . Vannucchi, A. M. (2018). Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia, 32(5), 1200-1210. doi:10.1038/s41375-018-0019-y Tefferi, A., Nicolosi, M., Mudireddy, M., Lasho, T. L., Gangat, N., Begna, K. H., . . . Pardanani, A. (2018). Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. Leukemia, 32(5), 1189-1199. doi:10.1038/s41375-018-0018-z Tefferi, A., Nicolosi, M., Mudireddy, M., Szuber, N., Finke, C. M., Lasho, T. L., . . . Vannucchi, A. M. (2018). Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. Am J Hematol, 93(3), 348-355. doi:10.1002/ajh.24978 Tefferi, A., Partain, D. K., Palmer, J. M., Slack, J. L., Roy, V., Hogan, W. J., . . . Patnaik, M. M. (2018). Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. Am J Hematol, 93(5), 649-654. doi:10.1002/ajh.25053 Tefferi, A., Saeed, L., Hanson, C. A., Ketterling, R. P., Pardanani, A., Gangat, N. (2017). Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis. Leukemia, 31(12), 2851-2852. doi:10.1038/leu.2017.268 Thomas, D. A., Giles, F. J., Albitar, M., Cortes, J. E., Verstovsek, S., Faderl, S., . . . Kantarjian, H. M. (2006). Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer, 106(9), 1974-1984. doi:10.1002/cncr.21827 Tutschka, P. J., Copelan, E. A., Klein, J. P. (1987). Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood, 70(5), 1382-1388. Vannucchi, A. M., Lasho, T. L., Guglielmelli, P., Biamonte, F., Pardanani, A., Pereira, A., . . . Tefferi, A. (2013). Mutations and prognosis in primary myelofibrosis. Leukemia, 27(9), 1861-1869. doi:10.1038/leu.2013.119 Verstovsek, S., Kantarjian, H., Mesa, R. A., Pardanani, A. D., Cortes-Franco, J., Thomas, D. A., . . . Tefferi, A. (2010). Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med, 363(12), 1117-1127. doi:10.1056/NEJMoa1002028 Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., . . . Kantarjian, H. M. (2012). A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med, 366(9), 799-807. doi:10.1056/NEJMoa1110557 Zandvakili, I., Conboy, C. B., Ayed, A. O., Cathcart-Rake, E. J., Tefferi, A. (2018). Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A second experience. Am J Hematol, 93(5), E123-e125. doi:10.1002/ajh.25063 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56372 | - |
dc.description.abstract | 背景 血液學的治療日新月異,而近年來即使有了新的治療,包括JAK-STAT信號傳送途徑抑制劑以及其他免疫治療,異體造血幹細胞移植仍被視為骨髓纖維化病人唯一的治癒性治療。在此同時,移植前的前置性化學治療所帶來的毒性一直是醫師與病人共同非常在意的;而移植後幹細胞植入失敗和疾病的復發,也對病人的長期存活有很深的影響。當今對於骨髓纖維化病患接受移植前的前置化療強度並沒有共識,過去也未曾有隨機對照的臨床試驗針對不同強度的前置性化學治療對於移植後的治療成果做出比較。本研究的目的在於比較骨髓纖維化病人在移植前接受清髓性化學治療或者減低強度化學治療,對於移植預後的影響。 方法 作者進行系統性回顧及統合分析,搜尋發表在PubMed、EMBASE和Cochrane Library的文獻。文獻納入條件為經學者評審、有10位以上病人、同一文獻中包含分別接受清髓性治療和減低強度治療的病人。至西元2019年12月1日,共有387 篇文獻被初步審閱,最後有10篇文章納入此研究。總計有2776位病人, 其中1048位接受了清髓性治療,1728位接受了減低強度的前置化學治療。 結果 清髓性治療相對於減低強度治療,各滿足點的勝算比分別如下:三年整體存活率:1.48(百分之95信賴區間〔95% confidence interval,CI〕:0.71-3.08);五年整體存活率:0.88(95% CI:0.35-2.19);三年疾病無惡化存活率:0.81(95% CI:0.42-1.59);幹細胞植入失敗率:0.66(95% CI:0.51-0.86);非復發死亡率:0.92(95% CI:0.48-1.77);疾病復發率:0.56(95% CI:0.27-1.17);急性排斥累積發生率:1.39(95% CI:0.45-4.30);慢性排斥累積發生率:1.30(95% CI:0.40-4.19)。 結論 骨髓纖維化病人在造血幹細胞移植前接受清髓性或是減低強度治療,在三年整體存活率、五年整體存活率、三年疾病無惡化存活率、非復發死亡率、疾病復發率以及急、慢性排斥累積發生率方面,並無顯著差異,而接受清髓性前置化學治療的病人,有顯著較低的幹細胞植入失敗率。以前瞻性隨機對照試驗比較此二種治療的結果,雖然執行上不易,仍然可以給我們更多較少偏差的實證證據。 | zh_TW |
dc.description.abstract | Background Despite the advent of novel therapies, including JAK inhibitors and immunomodulatory agents, allogeneic hematopoietic stem cell transplant (Allo-HSCT) is viewed as the ultimate cure for myelofibrosis (MF). However, treatment toxicities of conditioning regimens are major concerns. Meanwhile, graft failure and relapse after the post-transplant course pose challenges against long-term survival. Currently, there’s neither firm consensus on the conditioning intensity in MF patients nor randomized controlled trials investigating the impact of dose intensity on the post-transplant outcome. This study aims to compare the outcomes of MF patients receiving either myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC) for Allo-HSCT. Patients and Methods We performed a systematic review and meta-analysis of the published literature extracted from PubMed, EMBASE, and the Cochrane Library. We restricted inclusion criteria to peer-reviewed studies that include both MAC and RIC regimes and more than 10 patients. As of Dec 1st, 2019, 387 potentially relevant studies were identified, but only 10 (2776 patients) met our criteria after evaluation. In total, 1048 patients received MAC regimens while 1728 patients received RIC regimens. Results The odds ratios of MAC/RIC of each endpoint are as following: overall survival (OS) at 3 years: 1.48 (95% confidence interval, CI: 0.71-3.08); OS at 5 years: 0.88 (95% CI: 0.35-2.19); progression-free survival (PFS) at 3 years: 0.81 (95% CI: 0.42-1.59); graft failure: 0.66 (95% CI: 0.51-0.86); non-relapse mortality (NRM): 0.92 (95% CI: 0.48-1.77); relapse incidence: 0.56 (95% CI: 0.27-1.17); and cumulative incidence of acute graft-versus-host disease (GVHD): 1.39 (95% CI: 0.45-4.30) and chronic GVHD: 1.30 (95% CI: 0.40-4.19). Conclusions There is no significant difference between MAC and RIC groups in regard to OS at 3 years and 5 years, PFS at 3 years, NRM, relapse incidence, and cumulative incidence of acute and chronic GVHD, whereas patients in the MAC group had lower graft failure rate. Prospective and randomized controlled trials are warranted to further investigate and compare outcomes of patients receiving different intensities of conditioning therapy, although it is challenging to initiate these trials. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T05:25:34Z (GMT). No. of bitstreams: 1 U0001-2707202011372800.pdf: 2851640 bytes, checksum: 815d30d519e8a1d7c72c3de41ba4993b (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 口試委員會審定書……………………………………………………………… i 謝辭…………………………………………………………………………………………… ii 中文摘要………………………………………………………………………………… iii 英文摘要………………………………………………………………………………… v 碩士論文內容 Introduction……………………………………………………………………… 1 Method……………………………………………………………………………………… 7 Result……………………………………………………………………………………… 12 Discussion…………………………………………………………………………… 15 Referenc………………………………………………………………………………… 20 Table 1…………………………………………………………………………………… 30 Table 2…………………………………………………………………………………… 32 Figure 1………………………………………………………………………………… 33 Figure 2………………………………………………………………………………… 34 Figure 3………………………………………………………………………………… 35 Figure 4………………………………………………………………………………… 36 Supplement Figure 1……………………………………………………… 37 Supplement Figure 2……………………………………………………… 39 Protocol of proposed clinical trial…………… 41 | |
dc.language.iso | en | |
dc.title | 異體造血幹細胞移植之前置化療強度對於骨髓纖維化病人之影響:系統性回顧、統合分析與臨床試驗計畫書 | zh_TW |
dc.title | Conditioning intensity of allogeneic hematopoietic stem cell transplantation in myelofibrosis: a systematic review and meta-analysis, with a proposed protocol | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-2 | |
dc.description.degree | 碩士 | |
dc.contributor.author-orcid | 0000-0003-4483-5627 | |
dc.contributor.oralexamcommittee | 林家齊(Chia-Chi Lin) | |
dc.subject.keyword | 骨髓纖維化,異體造血幹細胞移植,前置化療之強度,系統性回顧,統合分析, | zh_TW |
dc.subject.keyword | myelofibrosis,hematopoietic stem cell transplant,conditioning intensity,systematic review,meta-analysis, | en |
dc.relation.page | 97 | |
dc.identifier.doi | 10.6342/NTU202001899 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2020-07-31 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-2707202011372800.pdf 目前未授權公開取用 | 2.78 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。